Related Experiment Video

Updated: Apr 3, 2026

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

7.0K

Interleukin-33/ST2 axis in Kawasaki disease: biology, vascular pathology, and future therapeutic strategies

Seigo Okada1,2,3, Pui Y Lee2, Hiroki Yasudo4

  • 1Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan.

Expert Review of Clinical Immunology
|April 1, 2026
PubMed

Insights

The interleukin-33 (IL-33)/suppression of tumorigenicity 2 (ST2) axis may modulate Kawasaki disease (KD) inflammation and injury. Targeting this pathway could prevent coronary artery abnormalities (CAAs) in KD patients.

Area of Science:

  • Immunology
  • Vascular Biology
  • Pediatric Vasculitis

Background:

  • Kawasaki disease (KD) is a leading cause of acquired heart disease in children.
  • Coronary artery abnormalities (CAAs) are significant complications of KD, necessitating better understanding.
  • The role of the IL-33/ST2 axis in KD pathogenesis requires further elucidation.

Purpose of the Study:

  • To review the current understanding of the IL-33/ST2 signaling pathway in Kawasaki disease.
  • To explore the potential contribution of IL-33/ST2 to vascular inflammation and injury in KD.
  • To assess the therapeutic potential of targeting the IL-33/ST2 axis for preventing CAAs.

Main Methods:

  • Comprehensive literature search of biomedical databases (PubMed, ClinicalTrials.gov).
  • Integration of evidence from clinical studies, biomarker analyses, and experimental KD models.
  • Focus on the molecular biology, signaling, and immunological effects of IL-33/ST2.

Main Results:

  • The IL-33/ST2 axis is implicated as a pathway linking tissue injury, immune activation, and vascular inflammation in KD.
  • Soluble ST2 shows potential as a biomarker for KD disease activity and cardiac stress.
  • IL-33/ST2 signaling appears to play a context-dependent role in KD pathogenesis.

Conclusions:

  • The IL-33/ST2 axis is a plausible modulatory pathway in Kawasaki disease.
  • Targeting IL-33/ST2 signaling offers a potential therapeutic strategy for preventing CAAs.
  • Biomarker-guided modulation of IL-33/ST2 could represent a next-generation treatment approach for KD.
Abstract

Keywords:
Acquired heart diseaseacute coronary syndromealarmincoronary artery aneurysmdamage-associated molecular patternvasculitis

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.9K
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.3K
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
466
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
949
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
324
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
583